CliffBio
small molecule

DEXLANSOPRAZOLE

DEXLANSOPRAZOLE

Loss of exclusivity—loss of exclusivity
CompanyTWI PHARMACEUTICALS INC

Drug detail

Brand nameDEXLANSOPRAZOLE
Active ingredientDEXLANSOPRAZOLE
Strength60MG
Dosage formCAPSULE, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2022
Marketing statusRX

More from TWI PHARMACEUTICALS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.